Last reviewed · How we verify

glulisine insulin, glargine insulin

Population Health Research Institute · Phase 3 active Small molecule

glulisine insulin, glargine insulin is a insulin analog Small molecule drug developed by Population Health Research Institute. It is currently in Phase 3 development for Type 1 diabetes, Type 2 diabetes. Also known as: Apidra, Lantus.

Glulisine insulin and glargine insulin are long-acting insulin analogs that mimic the action of human insulin, stimulating glucose uptake in cells and lowering blood glucose levels.

Glulisine insulin and glargine insulin are long-acting insulin analogs that mimic the action of human insulin, stimulating glucose uptake in cells and lowering blood glucose levels. Used for Type 1 diabetes, Type 2 diabetes.

At a glance

Generic nameglulisine insulin, glargine insulin
Also known asApidra, Lantus
SponsorPopulation Health Research Institute
Drug classinsulin analog
Targetinsulin receptor
ModalitySmall molecule
Therapeutic areaDiabetes
PhasePhase 3

Mechanism of action

Glulisine insulin and glargine insulin work by binding to insulin receptors on the surface of cells, triggering a signaling cascade that ultimately leads to the uptake of glucose from the bloodstream into cells. This process helps to lower blood glucose levels and improve glycemic control.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about glulisine insulin, glargine insulin

What is glulisine insulin, glargine insulin?

glulisine insulin, glargine insulin is a insulin analog drug developed by Population Health Research Institute, indicated for Type 1 diabetes, Type 2 diabetes.

How does glulisine insulin, glargine insulin work?

Glulisine insulin and glargine insulin are long-acting insulin analogs that mimic the action of human insulin, stimulating glucose uptake in cells and lowering blood glucose levels.

What is glulisine insulin, glargine insulin used for?

glulisine insulin, glargine insulin is indicated for Type 1 diabetes, Type 2 diabetes.

Who makes glulisine insulin, glargine insulin?

glulisine insulin, glargine insulin is developed by Population Health Research Institute (see full Population Health Research Institute pipeline at /company/population-health-research-institute).

Is glulisine insulin, glargine insulin also known as anything else?

glulisine insulin, glargine insulin is also known as Apidra, Lantus.

What drug class is glulisine insulin, glargine insulin in?

glulisine insulin, glargine insulin belongs to the insulin analog class. See all insulin analog drugs at /class/insulin-analog.

What development phase is glulisine insulin, glargine insulin in?

glulisine insulin, glargine insulin is in Phase 3.

What are the side effects of glulisine insulin, glargine insulin?

Common side effects of glulisine insulin, glargine insulin include Hypoglycemia, Weight gain, Allergic reactions.

What does glulisine insulin, glargine insulin target?

glulisine insulin, glargine insulin targets insulin receptor and is a insulin analog.

Related